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Objectives: Heterogeneity can distort traditional indirect comparisons of treat-
ments. Simulated treatment comparisons (STC) can overcome this with regres-
sion equations to balance differences in populations. Equations are derived using 
patient-level data from one trial (drug A, index); however, only mean values of 
predictors are typically known for the comparator (B). Thus, adjusted results must 
be generated by plugging these means in the equation, which can be biased for 
non-linear outcomes (e.g., time-to-event) since it yields the geometric rather than 
the required arithmetic mean. We describe a solution and illustrate its application 
in an STC of treatments of non-valvular atrial fibrillation (NVAF). MethOds: Data 
from the trial of drug A were used to derive an equation for the rate of major bleeds 
(MB) using Poisson regression. Predictors included gender, age, region, history of 
stroke/transient ischemic attack, hypertension, diabetes, renal dysfunction, prior 
use of various treatments. To avoid non-linearity bias, patient profiles were simu-
lated by sampling predictor values from a multivariate-normal distribution with 
means set to drug B’s population and covariance matrix derived from the index 
trial. The average predicted rate for simulated patients represents the adjusted 
MB rate. To demonstrate that the approach works, we also apply it to the index 
trial. Results: A rate of 21 MBs/1000 person-years were observed with drug A. The 
predicted rate at the means of predictors of patients on drug A produced an estimate 
of 19 (16.4-21.0), whereas the mean of predicted rates with actual profiles was 22 
(15.1-31.9). Repeating the calculations with simulated patients yielded 22.5 (15.3-
33.0). The simulated MB rate in patients matching of the population of drug B was 
30 (20.5-45.1), which contrasted with its observed rate (36.0) yielded a rate ratio of 
0.84 (0.56-1.27). cOnclusiOns: Predicting outcomes with a simulated comparator 
population produces accurate adjusted results for use in STCs.
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Objectives: To evaluate new medicines, Health Technology Assessment (HTA) 
agencies must have comparative data. With the lack of randomized trials versus all 
comparators, pharmaceutical companies have increasingly used indirect compari-
sons. The objective of the present study was to describe the impact of the method-
ology of the indirect comparison both on the ASMR determination and efficiency 
opinions given by the French National Authority for Health (HAS). MethOds: Two 
retrospective studies were conducted in order to select HTA opinions mention-
ing indirect comparisons (using the keywords “indirect” or “network”) using inter-
nal databases of HAS. The first study was related on HTA opinions given by the 
Transparency Committee (TC) from July 2009 to October 2014. The second study 
analyzed efficiency opinions issued by the Commission of Economic Evaluation 
and Public Health (CEESP) from October 2013 to December 2014. For each study, 
we recorded: the method of indirect comparison used, the acceptability, the criti-
cisms and the impact on decision-making. Results: We identified 61 indirect com-
parisons from HTA opinions given by the TC. Among these, the TC considered 30 
methodologically unacceptable. Network meta-analysis, the method recommended 
by the HAS, was used in 46% of cases. Only 6/61 indirect comparisons were valid, 
allowing to prioritize the treatment, and were consistent with the « improvement 
of the medical service provided » (ASMR) assigned. In the second study out of 14 
opinions of efficiency given by the CEESP, 4 included indirect comparisons (29%) and 
they were all considered as acceptable. cOnclusiOns: For the TC, the results of 
indirect comparisons are considered as complementary evidence, and are not deci-
sive elements for the ASMR opinion. Conversely, CEESP accepted more frequently 
results of indirect comparisons into economic evaluations. This apparent difference 
in considering and using indirect comparisons by these two commissions of the 
HAS may be explained by their different objectives.
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Objectives: To propose a sample size calculation method for randomized trial-
based cost-effectiveness analyses (RTBCEA), coherent with recommendations to 
express uncertainty through cost-effectiveness probabilities and expected value of 
information. MethOds: Let’s estimate the sample size of a RTBCEA with 2 parallel-
groups of equal size n, assuming equal variance of costs (s²C) and effectiveness 
(s²E) in each group. Our method is based on the incremental net monetary benefit 
(b~N(μ b,σ ²b)). A realization of this random variable in the planned RTBCEA would 
yield a sampling distribution of mean μ b and variance 2σ ²bi/n, where σ ²biis the vari-
ance of the individual net monetary benefit in each group. σ ²bi= λ ²σ ²E+σ ²C–2λ ρ σ Eσ C, 
where λ is the ceiling cost-effectiveness ratio, and ρ the correlation between cost and 
effectiveness. Using this sampling distribution of b, the remaining value of perfect 
information (or the expected value of perfect information depending on n (EVPI(n))) 
is calculated, specifying the size of the target population (N) and a discount rate 
(r). The total cost of the planned RTBCEA is defined by a fixed cost (Cf) and a cost/
patient (Cv). The optimal sample size of one arm in the planned RTBCEA is n when 
EVPI(n)= Cf+2nCv. An application compares sample sizes calculated through our 
method and through a method using statistical inference. Results: Application’s 
data are: σ C= 2100€ , σ E= 2100QALY, ρ = 0.1, λ = 20000€ /QALY, N= 52000/year, r= 0.04, 
time horizon for the calculation of EVPI= 20 years, difference in mean costs= -168€ , 
and difference in mean QALY= 0.04. σ ²bi= 9162002.53 Cf= 81531€ , and Cv= 2257.25€ 
The optimal sample size estimated through our method was 123 patients/group, 
compared to 153/group using the method based on a statistical test with a 80% 
power and a 5% alpha risk. cOnclusiOns: Our method is perfectly coherent with 
recommendations for analyzing cost-effectiveness data and sets the optimal sample 
NICE, IQWiG, CADTH, HAS and EUnetHTA) were reviewed to identify recommen-
dations made forBayesian NMAs in the context of HTAs. Examples of HTA sub-
missions from manufacturers were used to identify how Bayesian results are 
reported in practiceIn order to ensure clarity and simplicity, a guide to interpret 
these results was developed in collaboration with analysts not trained in Bayesian 
statistics. This guide is illustrated with an example of NMA. Results: Bayesian 
analyses are often used in the conduct of NMAs meant to inform cost-effectiveness 
models. Results are generally reported as median or mean of the posterior distribu-
tion, standard deviation, 95% credible intervals and forest plots. Additional results 
include the probability for each treatment of ranking first, the SUCRA (Surface 
Under the Cumulative Ranking) and the probability for the intervention to perform 
better than its comparators. Although it could help interpret the findings, graphi-
cal representation of the posterior distribution is not commonly reported in HTA. 
Sensitivity analyses are also often reported, mainly to assess the robustness of 
the results. cOnclusiOns: Our guide is useful to analysts not trained in Bayesian 
statistics for decision-making purposes in the context of HTA submissions. More 
specifically, it is a straightforward reference tool for using NMA results to populate 
cost-effectiveness models.
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non-adheRence and non-PeRsIsTence shoUld be analyzed sePaRaTely: 
The exaMPle of MeThoTRexaTe (MTx) TheRaPy In The TheRaPy of newly 
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Objectives: In most adherence studies, results are shown as overall medication 
possession ratio (MPR). The aim of this study was to show how non-adherence 
(NA) rates of German patients with rheumatoide arthritis (RA) having initiated a 
methotrexate (MTX) therapy change if adherence is analyzed as overall MPR includ-
ing periods of therapy discontinuation (NP) or, alternatively, for periods of treat-
ment continuation only. MethOds: Claims data from a German sickness fund 
(AOK PLUS) covering the years 2010-2013 were used. Minimum observational period 
from first MTX-prescription onwards was defined to be 24 months. A medication gap 
of more than 12 weeks was considered to be NP. Adherence was calculated during 
a 12 or 24 month follow-up in two scenarios (for whole period versus for periods 
of therapy continuation between first and last prescription only). NA was defined 
as MPR< 80%. Results: 1,157 MTX-naïve patients (no MTX-prescription in 2010) 
were identified (mean age 61.6 years, 71.8% female, average Charlson Comorbidity 
Index without age factor 2.0). Overall MPR from first prescription until end of the 
12- or 24-months-obserational period for all these patients was 69.7 or 59.9%. Based 
on this, percentage of NA patients was 41.2 or 53.3%. However, 21.2% of patients 
discontinued MTX therapy (NP) within the first 24 months; mean time to discon-
tinuation was 29.1 weeks. If adherence was assessed for periods of therapy con-
tinuation only, the resulting MPR was 95.0% with only 6.4% of patients affected by 
NA. cOnclusiOns: NA and NP describe different real-world phenomena in the 
drug-based treatment of patients and may also be explained by different causes. So, 
NP and NA should be assessed separately. Our analysis shows that the percentage 
of patients poorly implementing therapy is over-estimated if NA is not calculated 
for periods of therapy continuation only.
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Objectives: Typical survival analysis examines differences in curves across the 
entire spectrum of time. Often the research question relates to differences in sur-
vival at a single point in time without considering other aspects of the survival 
curve. MethOds: This research used data from the United States Surveillance, 
Epidemiology and End Results Program (US-SEER), comparing cervical and ovar-
ian cancer 5-year survival rates from 2007-2011. The steps in this analysis are: 1. 
Calculate Kaplan-Meier curve (or any survival curve) using standard methods, 2. 
Calculate the quadratic curve for the survival measure and record the formula. 
3. Using the point of interest (in this example 12 months) calculate the tangent 
line for that point, using the derivative power method. These two slope values are 
tested against each other using standard slope comparisons. 4. Use the standard 
error of the model for the quadratic equation for significance testing. 5. Test the 
difference between slopes for significance using standard statistical methods for 
slope comparisons. Results: Quadratic formulas were determined for both ovarian 
and cervical cancer survival curves and the tangent lines were calculated using the 
derivative for the equation from the curve. This resulted in two slope values at 12 
months (cervical 4.116 and ovarian 7.151). Using the standard errors for the cervix 
and ovarian groups (2.268 and 3.854 respectively), the Z-value= 0.6787 and p= 0.497, 
indicating the trajectory of survival for cervical and ovarian cancer are not statisti-
cally different from each other even though the point estimates of survival (88.4% 
for cervical; 75.4% for ovarian) are statistically different from each other at that 
point. cOnclusiOns: The strengths of this method is that a single point difference 
test can be conducted for a single point in time based on the trajectory of the line. 
This method does not pool the data across all points. Several other examples will 
be presented graphically.
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from NICE regarding inclusion of this methodology within HTA. Conclusions on the 
acceptance of this methodology by NICE cannot be made due to limited examples.
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evIdence RevIew gRoUPs In The Uk
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Objectives: The quality of evidence used in manufacturers’ submissions to health 
technology assessment (HTA) bodies is an important factor for the success of tech-
nology appraisals (TA). Indirect comparisons (IC) and network meta-analyses (NMA) 
are used in health policy decisions via the clinical effectiveness evidence in HTA 
submissions to the National Institute for Health and Care Excellence (NICE). The 
aim of this study was to: (i) assess the use of ICs and NMAs in HTA submissions 
to NICE; (ii) identify criticisms of ICs and NMAs in TAs generated by NICE and the 
Evidence Review Group (ERG); (iii) provide key insights and recommendations to 
minimise criticism of an IC or NMA in future HTA submissions. MethOds: The 
NICE website was interrogated to identify both TAs and the associated ERG/final 
appraisal document reports published from January 2013 to June 2015 in any thera-
peutic setting. Results: A large proportion of the TAs analysed included ICs or 
NMAs. Common criticisms were related to the identification of data and the study 
selection for inclusion, study heterogeneity and the inadequate reporting of meth-
ods and analyses. cOnclusiOns: The majority of criticisms of evidence synthesis 
submitted to NICE were related to issues around the primary evidence included in 
the analyses rather than the statistical methods of the analyses. To avoid many of 
the criticisms identified in this study a transparent approach to the reporting of the 
ICs and NMAs (and systematic review) is recommended.
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Objectives: Network meta-analysis (NMA) of clinical trial outcomes is usually 
based on Bayesian statistics and hence requires software for Monte Carlo Markov 
chain (MCMC) sampling. The most common choice of software for NMA is WinBUGS, 
in part because there is a large body of WinBUGS code for NMA in the literature; for 
example in the NICE Decision Support Unit (DSU) Technical Support Documents 
(TSD) on evidence synthesis. However, WinBUGS is slow, difficult to use, and bet-
ter, more efficient, options may be available. This project aimed to identify and 
evaluate alternatives to WinBUGS. MethOds: We identified candidate alternatives 
for evaluation via journal articles and websites. We performed an initial examina-
tion against a set of criteria including (a) compatibility with Windows (b) speed (c) 
ease of use (d) publication quality graphics (in the system or ease of linking with 
an external program such as R) (e) ability to handle large datasets within MCMC 
software and (f) cost. We ranked the candidates and then performed a validation 
of the top-ranked choice by running a set of examples found in the NICE DSU TSDs 
to ensure matching of the results. Results: We found nine potential alternatives 
to WinBUGS: OpenBUGS; JAGS; GeMTC; LaplacesDemon; Mamba; PyMC; SAS PROC 
MCMC; MCMCpack; Stan. Stan was the most promising and we tested it against a 
number of datasets used from the NICE guidance. cOnclusiOns: We found Stan, 
an open source program for Bayesian statistical inference, to be the best option for 
NMA. Stan provides an excellent balance of model flexibility, allowing for manual 
user specification, and is easily integrated with R for producing publication qual-
ity graphics. We found it straightforward to learn because it is accompanied by an 
extensive user manual and provides helpful error messages. We recommend that 
NMA practitioners should consider Stan as an alternative to WinBUGS.
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accoRdIng To healTh exPendITURes
Cinaroglu S
Hacettepe University, Ankara, Turkey
Objectives: Machine learning techniques are used for analysis of large complex 
datasets. Classification is an important part of machine learning applications, it 
defines groups within population. There are many different methods which are 
compare results to determine the best classification. In this study we aim to use 
machine learning techniques to classify OECD countries according to their health 
expenditures. MethOds: Different algorithms can be use in machine learning tech-
niques; C4.5 which is an extension version of ID.3 algorithm and CART algorithm 
are one of these most commonly use algorithms. Random Forest which constructs 
a lot of number of trees is one of another useful technique for solving both clas-
sification and regression problems. In this study we compare classification per-
formances of different decision trees (C4.5, CART) and Random Forest which was 
generated by using 50 trees. We perform this prediction model for predicting OECD 
countries health expenditures for the year 2011. We use number of independent 
variables for this prediction. These are; life expectancy at birth, number of phy-
sicians, number of hospitals, hospital aggregates, alcohol consumption, GDP per 
capita, perceived health status and immunization. We use AUC results and ROC 
curve graph for performance comparison. Results: As a result of this study it was 
seen that classification performances of machine learning techniques were good 
(AUC≥ 0.90) and Random Forest [50] classification performance results much higher 
[AUC= 0.98] than CART (0.95) and C4.5 (0.90). Decision tree graphs shows that GDP 
per capita was a variable which has more information gain for predicting health 
expenditures. cOnclusiOns: To conclude according to our knowledge this is the 
first study applied machine learning classification methods to health expenditure 
data. Future studies will compare classification performances of Random Forest 
using different types of health expenditure datasets, different predictor variables 
while increasing the number of trees in the forest.
size of an RTBCEA that balances its cost and the value of perfect information that 
would remain after its completion.
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Objectives: Quantitative analysis of spontaneous adverse drug reaction reports 
is increasingly used in drug safety research. Signals are detected by disproportion-
ality measures (DM). Different types of DMs are available: a debate is ongoing on 
which performs better. The aim was to evaluate the sensitivity on identification of 
signals with known safety profiles of incretin drugs. MethOds: Adverse Events (AE) 
reported to FDA Adverse Event Reporting System (FAERS) between 2005 and 2014 
were included. To evaluate the impact of warning actions, two separated analysis 
were conducted: restricted to the time before and after a regulatory action. We 
selected 20 AEs for each drug, half as “positive controls” (with a known causal associ-
ation from literature) and half as “negative controls” (with no evidence in literature). 
Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), Bayesian Confidence 
Propagation Neural Network Analysis (BCPNN) and Gamma-Poisson Shrinker (GPS) 
were calculated on 120 combinations of AE-drugs. Correlation between sensitivity 
and number of AEs per year reported for each drug was calculated to evaluate the 
effect of number of reports on sensitivity. Results: The number of reports ana-
lyzed in 2014 was 1,934,607. After warning action, PRR showed a sensitivity of 0.42 
(0.29; 0.55), ROR 0.55 (0.42; 0.68), BCPNN 0.53 (0.40; 0.66) and GPS 0.23 (0.13; 0.36). 
Analog findings were observed before warning actions. The concordance of signals 
identification was good for all pairwise comparison between DMs (> 0.56). The cor-
relation varied among 0.49 (for PRR) and 0.82 (for ROR and BCPNN) after warning 
action. cOnclusiOns: The sensitivity of measures was low (< 0.6), without impact 
of warning actions. ROR and BCPNN showed the most elevated values of sensitivity 
not allowing to determine a clear superiority of neither frequentist nor bayesian 
DMs. As expected, the positive correlation suggests the presence of a strong impact 
on sensitivity of higher number of AEs reported.
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coRRecTIng foR swITchIng To second lIne TReaTMenT In The sURvIval 
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Objectives: Randomized clinical trials of biological products are commonly ana-
lyzed with an intent-to-treat (ITT) approach, whereby patients are analyzed in their 
assigned treatment group regardless of actual treatment received. The ensuing 
switch to second line treatment disturbs randomization, compromising the utility 
of clinical data. The main objective of the study is to discuss how the statistical 
procedure of inverse probability of censoring weighted (IPCW) analysis may be used 
in this situation MethOds: The first step in the IPCW analysis is to predict the 
probability of switch on the basis of each patient’s baseline characteristics, such 
as age, sex, race, the time from diagnosis to randomization, and biological markers 
by fitting a logistic regression model. Finally, Overall Survival (OS) is analyzed with 
the censored data set and observations weighted by the inverse of the predicted 
probability of censoring. The method was illustrated for one clinical trial evaluating 
the effect of one monoclonal antibody combined with gemcitabine in patients with 
advanced pancreatic cancer. Results: A total of 192 patients were randomized 
(average age 63.6 ±10 years; 60% male; 69% ECOG PS 0), Of 96 patients enrolled in the 
nimotuzumab arm (OSAG), 40 patients (41.7%) switch to second line, while in the 
Placebo arm 41(42.7%) switch to the second line. The hazard ratio and 95% CI for OS 
was 0.83 (95% CI, 0.62 to 1.12) for ITT, was 0.75 (95% CI, 0.51 to 1.12) for the censored 
analysis, and for IPCW was 0.82 (95% CI, 0.67 to 0.98). cOnclusiOns: The switch 
to second line treatment affects efficacy results of the ITT analysis of the nimotu-
zumab plus Gemcitabine therapy in pancreatic cancer. Additional IPCW analysis 
indicates that the benefit of the molecular antibody, nimotuzumab, is greater than 
that reflected by the ITT estimate.
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Objectives: Meta-analysis of survival data is most commonly performed by using 
the individual summary statistic hazard ratio (HR) from each study as an appropri-
ate measure of effect. The aim of this study was to (i) assess the literature reporting 
on the use of meta-analysis of parametric survival curves, an alternative novel 
method for the evidence synthesis of survival data; (ii) assess technology apprais-
als (TAs) submitted to the National Institute for Health and Care Excellence (NICE) 
to determine whether this novel method has been accepted within UK Health 
Technology Assessment (HTA). MethOds: Embase, Medline and the Cochrane 
Library were searched to identify publications reporting on novel statistical meth-
ods. The NICE website was interrogated to identify oncology TAs, the associated 
Evidence Review Group (ERG) and final appraisal document (FAD) as published 
between 2011 and 2014 which reported novel statistical methods. Results: Four 
publications reported on the use of meta-analysis of parametric survival curves. 
Of the most recent 60 NICE TAs, a single TA included the use of meta-analysis of 
parametric survival curves. cOnclusiOns: Meta-analysis of survival curves has 
been developed to address limitations which arise where the proportional hazards 
assumption does not hold for survival curves; however, to date the method has 
not been validated by independent statisticians and currently there is no guidance 
